Dashboard MRSA
Repurposing candidates for MRSA
Methicillin-resistant Staphylococcus aureus
Approved medicines with AI-predicted activity ≥40% against MRSA, leaving out medicines that are already antimicrobials. Each is shown with what it is already used for. They are surfaced computationally for further investigation, not as treatments.
- AI-predicted activity ≥40%
- 860
- Existing antimicrobials set aside
- 117
- Needing review
- 72
- Repurposing candidates
- 671
Repurposing candidates for MRSA
AI prediction · nothing measuredAll 671 repurposing candidates for MRSA.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ZafirlukastExisting use: Airway obstruction, Asthma58.8% AI-predicted activityagainst MRSA6 registered studies
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more58.8% AI-predicted activityagainst MRSA50+ registered studies
- PlicamycinExisting use: Neoplasm58.7% AI-predicted activityagainst MRSA3 registered studies
- Dasabuvir SodiumExisting use: Chronic hepatitis C virus infection, Hepatitis C virus infection, Viral disease58.7% AI-predicted activityagainst MRSANo documented evidence found
- DigoxinExisting use: Atrial fibrillation, Cardiovascular disease, Congestive heart failure and 1 more58.7% AI-predicted activityagainst MRSA50+ registered studies
- AcetyldigitoxinExisting use: Cardiovascular disease58.7% AI-predicted activityagainst MRSANo documented evidence found
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease58.6% AI-predicted activityagainst MRSA50+ registered studies
- Sonidegib PhosphateExisting use: Basal cell carcinoma, Neoplasm58.5% AI-predicted activityagainst MRSA2 registered studies
- LemborexantExisting use: Insomnia58.4% AI-predicted activityagainst MRSA50+ registered studies
- Umbralisib TosylateExisting use: Follicular lymphoma, Marginal zone B-cell lymphoma, Neoplasm58.4% AI-predicted activityagainst MRSANo documented evidence found
- Afatinib DimaleateExisting use: Non-small cell lung carcinoma58.4% AI-predicted activityagainst MRSA50+ registered studies
- TovorafenibExisting use: Low grade glioma58.4% AI-predicted activityagainst MRSA16 registered studies
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma58.2% AI-predicted activityagainst MRSA50+ registered studies
- Avatrombopag MaleateExisting use: Hemorrhage, Liver disease, Thrombocytopenia58.1% AI-predicted activityagainst MRSA6 registered studies
- Pacritinib CitrateExisting use: Neoplasm, Polycythemia vera, Primary myelofibrosis58.1% AI-predicted activityagainst MRSA2 registered studies
- Gilteritinib FumarateExisting use: Acute myeloid leukemia, Myeloid leukemia, Neoplasm58.1% AI-predicted activityagainst MRSA3 registered studies
- DeslanosideExisting use: Cardiovascular disease58.0% AI-predicted activityagainst MRSANo documented evidence found
- CeritinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma57.8% AI-predicted activityagainst MRSA50+ registered studies
- DocetaxelExisting use: Adenocarcinoma, Breast cancer, Breast carcinoma and 19 more57.8% AI-predicted activityagainst MRSA50+ registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more57.7% AI-predicted activityagainst MRSA50+ registered studies
- IrbesartanExisting use: Cardiovascular disease, Chronic kidney disease, Chronic renal failure syndrome and 3 more57.6% AI-predicted activityagainst MRSA50+ registered studies
- SitagliptinExisting use: Diabetes mellitus, Hyperlipidemia, Myocardial infarction and 2 more57.6% AI-predicted activityagainst MRSA50+ registered studies
- Ingenol MebutateExisting use: Actinic keratosis57.6% AI-predicted activityagainst MRSA50+ registered studies
- DigitoxinExisting use: Cardiovascular disease57.5% AI-predicted activityagainst MRSA3 registered studies